Actinic Keratosis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

The actinic keratosis (AK) treatment market is anticipated to grow at a CAGR of about 4.5% during the forecast period 2021-2029.

In skin care, occurrence of rough, scaly, crusty, thick patches on the skin surface showing premalignant condition is referred as actinic keratosis. Skin colour changes such as pink, brown or flesh color, hard wart type surface, rough, scaly surface, burning and it itching sensations are usually found symptoms of actinic keratosis. Usually, physical observation and skin biopsy are conducted to diagnose and confirm actinic keratosis. As per certain studies the prevalence rate of AK was about 1.95 per 10,000 people whose average was in 40s. However, this rate was about 31.81 for people with average of 80 and above.


People who are exposed to more level of sunlight, and people with fair skin have higher probability of acquiring actinic keratosis. The prevalence is higher in western countries than the Asian countries. Generally, next phase of actinic keratosis leads to squamous cell carcinoma. Squamous cell carcinoma is a kind of cancer and early treatment reduces the risk to life. Threat related with untreated actinic keratosis is 20% higher than treated actinic keratosis. Hence, it is advisable to treat early to avoid progression of actinic keratosis and eventually squamous carcinoma.

Lack of Awareness is A Key Restraining Factor

Factors such as global warming, depletion of ozone layer, increasing number of cancer cases, chronic skin diseases and problems, sedentary lifestyle are the key factors that are rising the prevalence of this is condition and therefore, the market for AK treatment. Whereas, lack of awareness related to actinic keratosis, is a major setback in the treatment of AK. Therefore, it becomes very essential to create awareness of AK and benefits of early treatment of AK so as to reduce the chances of progressing to a malignant stage.

Diagnosis Delayed Due To Pandemic

Due to COVID-19 there will be significant impact on global actinic keratosis market. Lockdowns, quarantines, social distancing, disturbed supply chain, constraints on travelling has been impacting routines and non essential services. People have been delaying visiting physicians and diagnostic centre unless it is for emergency. Similarly, healthcare institutions as filled with covid 19 patients have not been encouraging other patients to visit hospitals for non critical cases. This has significantly delayed the diagnosis and therefore, the treatment. All the more in the case of AK initial symptoms are not very severe to rush for emergency diagnosis. This has delayed the diagnosis of AK.

North America Leading the AK treatment Market

The global actinic keratosis market in this report is segmented by region as follows: North America, Europe, Asia Pacific and Rest of the World (RoW) regions. Currently, actinic keratosis market of North America is leading followed by Europe which is expected to grow comparatively at a higher rate. The reasons for growth of AK treatment market in North American and European actinic keratosis market are advanced healthcare infrastructure, awareness among people related to the disease and its treatment, high income, favourable regulatory framework and reimbursements.

Because of rapidly developing medical infrastructure, China and India are emerging markets in upcoming years. Overall, Asia Pacific region is showing significant growth over forecast period. Besides that, due to attention of Japanese government to improve the quality of healthcare facilities, Japanese market is expecting to portray boosting growth in coming years. Medical tourism will attract patients across the globe to Asia Pacific region. Increased income of people, rising literacy rate, increased spending on healthcare, demand for quality and effective treatments are the driving factors for the market growth.

Key Market Players

• Sun Pharmaceutical Industries Ltd.
• Nestle Skin Health Company
• Biofrontera AG
• Bausch Health Companies Inc.
• Novartis AG
• GlaxoSmithKline Plc.
• Leo Pharma A/S
• Almirall LLC
• Cipher Pharmaceuticals Inc.

Historical & Forecast Period

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2029.

Report Scope by Segments

Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of treatment categories and region.

Key questions answered in this report

• What are the key market segments in current scenario and in the future by treatment categories?
• What are the key market segments in current scenario and in the future by regions?
• What is the key impact of Covid-19 over market revenues and market determinants in the AK treatment market?
• What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
• What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
• How to overcome the current market challenges and leverage the opportunities in each of the market segment?
• Who are the key players in the AK treatment market and what are their key product categories and strategies?
• What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth?